Analysts Set Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Price Target at $20.89

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) has been assigned an average recommendation of "Buy" from the ten ratings firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, seven have given a buy rating and two have given a strong buy rating to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $20.89.

Several equities research analysts have weighed in on the company. Brookline Capital Management started coverage on Y-mAbs Therapeutics in a report on Thursday, December 5th. They issued a "buy" rating and a $17.00 target price for the company. Wedbush reaffirmed an "outperform" rating and issued a $23.00 price objective on shares of Y-mAbs Therapeutics in a research note on Friday. HC Wainwright reissued a "buy" rating on shares of Y-mAbs Therapeutics in a research report on Wednesday, December 11th. Finally, Oppenheimer started coverage on shares of Y-mAbs Therapeutics in a research report on Monday, November 18th. They issued an "outperform" rating and a $23.00 price target for the company.

Y-mAbs Therapeutics Price Performance

Shares of YMAB stock traded down $0.50 during mid-day trading on Friday, hitting $6.89. The company had a trading volume of 759,043 shares, compared to its average volume of 353,540. The company has a market capitalization of $308.60 million, a P/E ratio of -12.76 and a beta of 0.69. The stock's 50 day moving average price is $10.47 and its 200-day moving average price is $12.16. Y-mAbs Therapeutics has a 52-week low of $6.84 and a 52-week high of $20.90.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last announced its earnings results on Friday, November 8th. The company reported ($0.16) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.02). Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. The company had revenue of $18.46 million during the quarter, compared to analysts' expectations of $23.38 million. During the same quarter last year, the firm posted ($0.18) EPS. On average, equities research analysts expect that Y-mAbs Therapeutics will post -0.66 earnings per share for the current year.

Institutional Trading of Y-mAbs Therapeutics

Institutional investors have recently bought and sold shares of the stock. State Street Corp raised its holdings in shares of Y-mAbs Therapeutics by 50.4% in the third quarter. State Street Corp now owns 1,209,781 shares of the company's stock worth $15,909,000 after buying an additional 405,169 shares during the last quarter. Caligan Partners LP raised its stake in Y-mAbs Therapeutics by 105.3% in the 3rd quarter. Caligan Partners LP now owns 1,195,253 shares of the company's stock worth $15,718,000 after acquiring an additional 613,175 shares during the last quarter. Geode Capital Management LLC lifted its position in Y-mAbs Therapeutics by 6.2% during the 3rd quarter. Geode Capital Management LLC now owns 813,489 shares of the company's stock worth $10,699,000 after acquiring an additional 47,846 shares during the period. Dimensional Fund Advisors LP lifted its position in Y-mAbs Therapeutics by 15.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 484,431 shares of the company's stock worth $5,853,000 after acquiring an additional 65,732 shares during the period. Finally, Millennium Management LLC increased its holdings in shares of Y-mAbs Therapeutics by 23.8% in the second quarter. Millennium Management LLC now owns 349,784 shares of the company's stock valued at $4,225,000 after purchasing an additional 67,233 shares during the period. 70.85% of the stock is currently owned by institutional investors and hedge funds.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.